Connect CLL注册研究:美国199个中心1494例慢性淋巴细胞白血病患者的最终分析
Connect CLL注册研究是一项美国多中心前瞻性观察性队列研究,2010至2014年入组1494例慢性淋巴细胞白血病患者,以社区为主。中位随访46.6个月,一线治疗未达中位总生存,二线为63.0个月,三线及以上为38.0个月。一线BR或FCR较其他治疗改善无事件生存(HR 0.60)和总生存(HR 0.67);二线及以上伊布替尼较其他治疗改善总生存。
要点
- 中位随访46.6个月,一线治疗中位总生存未达到,二线63.0个月,三线及以上38.0个月。
- 一线BR或FCR较其他治疗与改善无事件生存(HR 0.60,P<.0001)和总生存(HR 0.67,P=.0162)相关。
- 二线及以上伊布替尼较其他治疗改善总生存:二线HR 0.279(P=.009),三线HR 0.441(P=.011),四线及以上HR 0.578(P=.043)。
核心结论
- 数据提示临床试验中一线FCR优于BR的优势可能未能在社区实践中体现,而二线接受新型药物改善了结局。
研究设计与样本
- Connect CLL注册研究为美国多中心前瞻性观察性队列研究,2010至2014年入组1494例慢性淋巴细胞白血病患者,以社区为主。
- 患者按入组时治疗线数(LOT)分组,中位随访46.6个月(范围0-63.0个月)。
主要发现
- 中位总生存:一线未达到,二线63.0个月(95%CI 46.0-63.0个月),三线及以上38.0个月(95%CI 33.0-47.0个月)。
- 各线最常用方案为苯达莫司汀联合利妥昔单抗(BR;33.5%)、氟达拉滨联合环磷酰胺和利妥昔单抗(FCR;21.4%)及利妥昔单抗单药(18.5%)。
- 一线BR与FCR的中位无事件生存相似(BR 59.0个月 vs FCR 55.0个月),中位总生存均未达到。
- 多因素分析中,一线BR或FCR较其他治疗与改善无事件生存(HR 0.60,P<.0001)和总生存(HR 0.67,P=.0162)相关。
- 伊布替尼较其他治疗改善总生存:二线HR 0.279(P=.009),三线HR 0.441(P=.011),四线及以上HR 0.578(P=.043)。
临床怎么用
- 原文结论指出,临床试验中一线FCR优于BR的优势可能未能在社区实践中体现,而二线接受新型药物改善了结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Optimal treatment of chronic lymphocytic leukemia (CLL) remains unclear. The Connect CLL Registry, a United States-based multicenter prospective observational cohort study, enrolled 1494 patients between 2010 and 2014 from predominantly community-based settings. Patients were grouped by line of therapy (LOT) at enrollment. With a median follow-up of 46.6 months (range, 0-63.0 months), median overall survival (OS) was not reached in LOT1, 63.0 months (95% confidence interval [CI], 46.0-63.0 months) in LOT2, and 38.0 months (95% CI, 33.0-47.0 months) in LOT≥3. Bendamustine and rituximab (BR; 33.5%); fludarabine, cyclophosphamide, and rituximab (FCR; 21.4%); and rituximab monotherapy (18.5%) were the most common regimens across LOTs. Median event-free survival (EFS) was similar in patients treated with BR (59.0 months) and FCR (55.0 months) in LOT1; median OS was not reached. In multivariable analysis, BR or FCR vs other treatments in LOT1 was associated with improved EFS (hazard ratio [HR], 0.60; P < .0001) and OS (0.67; P = .0162). Using the Kaplan-Meier product limit, ibrutinib vs other treatments improved OS in LOT2 (HR, 0.279; P = .009), LOT3 (0.441; P = .011), and LOT≥4 (0.578; P = .043). Prognostic modeling of death at 2 years postenrollment identified 3 risk groups: low (mortality rate, 6.2%), medium (14.5%), and high (27.4%). The most frequent adverse events across LOTs were pneumonia (11.6%) and febrile neutropenia (6.2%). These data suggest that advantages of LOT1 FCR over BR seen in clinical trials may not translate to community practice, whereas receiving novel LOT2 agents improved outcomes. This trial was registered at www.clinicaltrials.gov as NCT01081015.
引用
- Mato A, Nabhan C, Lamanna N, et al. The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv. 2020. PMID: 32271900. doi:10.1182/bloodadvances.2019001145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。